FILTER
LATEST INTERVIEWS
Dennys Spencer
DIRECTOR, AMBIPAR RESPONSE
Ambipar Response is expanding its Latin American presence.
Rogério Wehmuth & Andressa Wehmuth
OWNER AND DIRECTOR & LATIN AMERICA GENERAL MANAGER, QUIMISA
Quimisa discusses its plans to expand geographically and incorporate greater sustainability into its operations.
Rahul Nachane
MANAGING DIRECTOR, NGL FINE CHEM
NGL Fine Chem is a manufacturer of pharmaceuticals and intermediates for usage in the veterinary and human health.
Serigne Ndanck Mbaye
CEO, DHL GHANA
DHL Ghana is part of DHL group, which is the global leader in logistics.
Ajay Tandon
EXECUTIVE DIRECTOR, VEEDA CLINICAL RESEARCH PVT. LTD.
Veeda Clinical Research is an independent CRO which offers a fully integrated package to its clients.
Omar Mithá
CHAIRMAN AND CEO, NATIONAL HYDROCARBONS COMPANY (ENH), MOZAMBIQUE
"We have set an example for other African countries on how to strike a balance between nationalistic development objectives and the attraction of foreign investment. For a company to go deep offshore and spend billions of dollars, you need to create a friendly environment."
Welington Soares
CEO, NORTHERN DEVELOPMENT CORRIDOR (CDN)
The Northern Development Corridor (CDN) was a Mozambique government infrastructure that became a private concession, with its largest stakeholders being Vale and Mitsui.
Leon Krüger
MANAGER HYDROMETALLURGY, MINTEK
Mintek is in the process of restructuring towards a model focused on introducing more cutting-edge technology and innovation.
George Olivier & Manie Kriel
DIRECTOR & CEO, VBKOM
Mining engineering consultancy VBKOM anticipates an era of growth as the mining cycle picks up.
Mohan Jain
DIRECTOR, NAPROD LIFE SCIENCES
Naprod Life Sciences provides life-saving cancer medications at affordable prices to patients around the world.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
